Mabwell (Shanghai) Bioscience Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public, Subsidiary

Established: 2017-05-12

Employees: 1.4K

Market Cap: -

Website: https://www.mabwell.com

Clinical Trials

A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer

Phase 2

Conditions: Advanced Lung Cancer

Interventions: Drug: 6MW3211

First Posted Date: 2022-06-24

Last Posted Date: 2022-06-24

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT05431569

A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

Suspended

Conditions: Solid Tumors

Interventions: Drug: 8MW2311

First Posted Date: 2022-06-13

Last Posted Date: 2024-11-20

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 216

Registration Number: NCT05416749

Locations: 🇨🇳
The first affiliated hospital of bengbu medicial college, Bengbu, Anhui, China
🇨🇳
Hunan cancer hospital, Changsha, Hunan, China
🇨🇳
Jian Zhang, Shanghai, Shanghai, China

A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections

Phase 2

Conditions: Skin Infection

Interventions: Combination Product: 9MW1411 injection 2 combined with Linezolid
Combination Product: 9MW1411 injection placebo combined with Linezolid
Combination Product: 9MW1411 injection 1 combined with Linezolid

First Posted Date: 2022-04-21

Last Posted Date: 2022-04-21

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 90

Registration Number: NCT05339802

Locations: 🇨🇳
Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China

Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

Phase 3

Conditions: Diabetic Macular Edema

Interventions: Drug: 9MW0813
Drug: Aflibercept

First Posted Date: 2022-04-12

Last Posted Date: 2022-04-12

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 346

Registration Number: NCT05324774

Locations: 🇨🇳
Beijing tongren hospital affliated to capital medical university, Beijing, Beijing, China

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

Phase 1

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: 9MW0813
Drug: Aflibercept

First Posted Date: 2022-04-12

Last Posted Date: 2022-04-12

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT05324592

Locations: 🇨🇳
Beijing tongren hospital affliated to capital medical university, Beijing, Beijing, China

A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD

Phase 2

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: Lucentis
Drug: MW02

First Posted Date: 2022-03-28

Last Posted Date: 2022-03-28

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 433

Registration Number: NCT05297292

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Si Chuan, China

A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: 9MW2821

First Posted Date: 2022-02-01

Last Posted Date: 2022-06-15

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 208

Registration Number: NCT05216965

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Efficacy and Safety of MW031 in PMO Subjects

Phase 3

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: MW031
Drug: Placebo

First Posted Date: 2022-01-31

Last Posted Date: 2023-10-11

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 448

Registration Number: NCT05215977

Locations: 🇨🇳
Peking Union Hospital, Beijing, Beijing, China

A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection

Phase 1

Completed

Conditions: COPD
Asthma
Atopic Dermatitis

Interventions: Drug: 9MW1911 Injection Placebo
Drug: 9MW1911 Injection

First Posted Date: 2021-12-27

Last Posted Date: 2023-12-11

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT05170243

Locations: 🇨🇳
Shanghai Public Health Center, Shanghai, Shanghai, China

A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm

Phase 1

Recruiting

Conditions: Advanced Malignant Neoplasm

Interventions: Drug: Intravenous Infusion

First Posted Date: 2021-09-17

Last Posted Date: 2022-05-09

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 272

Registration Number: NCT05048160

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy